

# SAFETY DATA SHEET



## Mometasone Cream Formulation



Version 5.0      Revision Date: 06.04.2024      SDS Number: 1688405-00018      Date of last issue: 30.09.2023  
Date of first issue: 21.05.2017

---

### Section 1: Identification

**Product identifier** : Mometasone Cream Formulation

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

#### Manufacturer or supplier's details

Company : Organon & Co.  
Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302  
Telephone : +1-551-430-6000  
Emergency telephone number : +1-215-631-6999  
E-mail address : EHSSTEWARD@organon.com

---

### Section 2: Hazard identification

#### Classification of the substance or mixture

Reproductive toxicity : Category 2  
Long-term (chronic) aquatic hazard : Category 2

#### GHS Label elements, including precautionary statements

Hazard pictograms :

Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

P391 Collect spillage.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**Section 3: Composition/information on ingredients**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
White mineral oil (petroleum)	8042-47-5	>= 50 -< 70
2-Methyl-2,4-pentanediol	107-41-5	>= 10 -< 20
Titanium dioxide	13463-67-7	>= 1 -< 10
Mometasone	83919-23-7	>= 0.1 -< 0.25

**Section 4: First-aid measures****Description of necessary first-aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

**Most important symptoms and effects, both acute and delayed**

- Risks : Suspected of damaging the unborn child.
- Protection of first-aiders : First Aid responders should pay attention to self-protection,

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**Indication of any immediate medical attention and special treatment needed**

Treatment : Treat symptomatically and supportively.

---

**Section 5: Fire-fighting measures****Extinguishing media**

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

**Special hazards arising from the substance or mixture**

Specific hazards during fire-fighting : Vapours may form explosive mixtures with air.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Metal oxides

**Special protective actions for fire-fighters**

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

**Section 6: Accidental release measures****Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions**

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up**

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

---

## Mometasone Cream Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 1688405-00018	Date of last issue: 30.09.2023 Date of first issue: 21.05.2017
----------------	------------------------------	------------------------------	---

employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**Section 7: Handling and storage**
**Precautions for safe handling**

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe vapours.  
Do not swallow.  
Avoid contact with eyes.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Conditions for safe storage, including any incompatibilities**

- Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

---

**Section 8: Exposure controls/personal protection**
**Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of	Control parameters / Permissible	Basis
------------	---------	------------------------	----------------------------------	-------

# SAFETY DATA SHEET



## Mometasone Cream Formulation



Version 5.0      Revision Date: 06.04.2024      SDS Number: 1688405-00018      Date of last issue: 30.09.2023  
 Date of first issue: 21.05.2017

		exposure)	concentration	
White mineral oil (petroleum)	8042-47-5	PEL (long term) (Mist)	5 mg/m <sup>3</sup>	SG OEL
		PEL (short term) (Mist)	10 mg/m <sup>3</sup>	SG OEL
		TWA (Inhalable particulate matter)	5 mg/m <sup>3</sup>	ACGIH
2-Methyl-2,4-pentanediol	107-41-5	PEL (short term)	25 ppm 121 mg/m <sup>3</sup>	SG OEL
		TWA (Vapour)	25 ppm	ACGIH
		STEL (Vapour)	50 ppm	ACGIH
		STEL (Inhalable fraction, Aerosol only)	10 mg/m <sup>3</sup>	ACGIH
Titanium dioxide	13463-67-7	PEL (long term)	10 mg/m <sup>3</sup>	SG OEL
		TWA (Respirable particulate matter)	2.5 mg/m <sup>3</sup> (Titanium dioxide)	ACGIH
Mometasone	83919-23-7	TWA	1 µg/m <sup>3</sup> (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

**This substance(s) is not bioavailable and therefore does not contribute to a dust inhalation hazard.**

Titanium dioxide

**Appropriate engineering control measures** : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

**Individual protection measures, such as personal protective equipment (PPE)**

Eye/face protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin protection : Work uniform or laboratory coat. Additional body garments should be used based upon the

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

---

**Section 9: Physical and chemical properties**

Appearance : cream

Colour : white to off-white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : > 93.3 °C

Evaporation rate : Not applicable

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics		
Particle size	:	No data available

---

**Section 10: Stability and reactivity**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Vapours may form explosive mixture with air. Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**Section 11: Toxicological information**

Information on likely routes of exposure	:	Skin contact Ingestion Eye contact
--	---	--

**Acute toxicity**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5 mg/l Exposure time: 4 h Test atmosphere: dust/mist Assessment: The substance or mixture has no acute inhala-

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

tion toxicity

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity

**2-Methyl-2,4-pentanediol:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 420

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

**Titanium dioxide:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity

**Mometasone:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg  
Application Route: Subcutaneous  
Symptoms: Breathing difficulties

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

Species : Rabbit  
Result : No skin irritation



## Mometasone Cream Formulation

Version 5.0      Revision Date: 06.04.2024      SDS Number: 1688405-00018      Date of last issue: 30.09.2023  
Date of first issue: 21.05.2017

---

**2-Methyl-2,4-pentanediol:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Titanium dioxide:**

Species : Rabbit  
Result : No skin irritation

**Mometasone:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

Species : Rabbit  
Result : No eye irritation

**2-Methyl-2,4-pentanediol:**

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405

**Titanium dioxide:**

Species : Rabbit  
Result : No eye irritation

**Mometasone:**

Species : Rabbit  
Result : No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

Test Type : Buehler Test

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

Exposure routes	: Skin contact
Species	: Guinea pig
Result	: negative

**2-Methyl-2,4-pentanediol:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative

**Titanium dioxide:**

Test Type	: Local lymph node assay (LLNA)
Exposure routes	: Skin contact
Species	: Mouse
Result	: negative

**Mometasone:**

Test Type	: Maximisation Test
Exposure routes	: Dermal
Species	: Guinea pig
Assessment	: Does not cause skin sensitisation.
Result	: negative
Remarks	: The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials

**2-Methyl-2,4-pentanediol:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	: Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

**Titanium dioxide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Result: negative

**Mometasone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: Mouse Lymphoma  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Test Type: Chromosomal aberration  
Species: Rat  
Cell type: Bone marrow  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

**Components:****White mineral oil (petroleum):**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 24 Months
Result	: negative

**Titanium dioxide:**

Species	: Rat
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 2 Years
Method	: OECD Test Guideline 453
Result	: positive
Remarks	: The mechanism or mode of action may not be relevant in humans. This substance(s) is not bioavailable and therefore does not contribute to a dust inhalation hazard.

Carcinogenicity - Assessment	: Limited evidence of carcinogenicity in inhalation studies with animals.
------------------------------	---

**Mometasone:**

Species	: Rat
Application Route	: Inhalation
Exposure time	: 2 Years
Dose	: 0.067 mg/kg body weight
Result	: negative

Species	: Mouse
Application Route	: Inhalation
Exposure time	: 19 Months
Dose	: 0.160 mg/kg body weight
Result	: negative

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****White mineral oil (petroleum):**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Skin contact Result: negative
----------------------	--

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative
-------------------------------	--

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

**2-Methyl-2,4-pentanediol:**

- |                                    |   |  |
|------------------------------------|---|--|
| Effects on fertility               | : | Test Type: One-generation reproduction toxicity study<br>Species: Rat<br>Application Route: Ingestion<br>Method: OECD Test Guideline 443<br>Result: negative |
| Effects on foetal development      | : | Test Type: One-generation reproduction toxicity study<br>Species: Rat<br>Application Route: Ingestion<br>Method: OECD Test Guideline 443<br>Result: positive |
| Reproductive toxicity - Assessment | : | Some evidence of adverse effects on development, based on animal experiments.  |

**Mometasone:**

- |                               |   |   |
|-------------------------------|---|---|
| Effects on fertility          | : | Test Type: Fertility<br>Species: Rat<br>Application Route: Subcutaneous<br>Fertility: NOAEL: 0.015 mg/kg body weight<br>Symptoms: Reduced embryonic survival, Reduced foetal weight<br>Result: No effects on fertility, Effect on reproduction capacity |
| Effects on foetal development | : | Test Type: Embryo-foetal development<br>Species: Mouse<br>Application Route: Subcutaneous<br>Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight<br>Result: Embryotoxic effects., Teratogenicity and developmental toxicity                           |
|                               |   | Test Type: Embryo-foetal development<br>Species: Rat<br>Application Route: Dermal<br>Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight<br>Result: Embryo-foetal toxicity   |
|                               |   | Test Type: Embryo-foetal development<br>Species: Rabbit<br>Application Route: Dermal<br>Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight<br>Result: Embryo-foetal toxicity, Malformations were observed.   |
|                               |   | Test Type: Embryo-foetal development<br>Species: Rat<br>Application Route: Subcutaneous<br>Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight<br>Result: Effects on newborn  |
|                               |   | Test Type: Embryo-foetal development  |

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

	Species: Rabbit
	Application Route: Oral
	Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
	Result: Embryo-foetal toxicity, Malformations were observed.
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**Components:****Mometasone:**

Remarks	: Based on available data, the classification criteria are not met.
---------	---

**STOT - repeated exposure**

Not classified based on available information.

**Components:****Mometasone:**

Exposure routes	: inhalation (dust/mist/fume)
Target Organs	: Immune system, Liver, Kidney, Skin
Assessment	: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****White mineral oil (petroleum):**

Species	: Rat
LOAEL	: 160 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Species	: Rat
LOAEL	: >= 1 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 4 Weeks
Method	: OECD Test Guideline 412

**2-Methyl-2,4-pentanediol:**

Species	: Rat
NOAEL	: >= 450 mg/kg
Application Route	: Ingestion
Exposure time	: 13 Weeks
Method	: OECD Test Guideline 408

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

**Titanium dioxide:**

Species	: Rat
NOAEL	: 24,000 mg/kg
Application Route	: Ingestion
Exposure time	: 28 Days

Species	: Rat
NOAEL	: 10 mg/m <sup>3</sup>
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 2 yr

**Mometasone:**

Species	: Rat
NOAEL	: 0.005 mg/kg
LOAEL	: 0.3 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	: Dog
LOAEL	: 0.5 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	: Rat
NOAEL	: 0.00013 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 90 d
Target Organs	: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species	: Dog
NOAEL	: 0.0005 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 90 d
Target Organs	: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

**Aspiration toxicity**

Not classified based on available information.

**Components:****Mometasone:**

|| Not applicable

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

**Experience with human exposure****Components:****2-Methyl-2,4-pentanediol:**

Eye contact	:	Target Organs: Eyes Symptoms: Irritation
-------------	---	---

**Mometasone:**

Inhalation	:	Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	:	Symptoms: Dermatitis, Itching

**Further information****Components:****Mometasone:**

Remarks	:	Dermal absorption possible
---------	---	----------------------------

---

**Section 12: Ecological information****Toxicity****Components:****White mineral oil (petroleum):**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	:	NOEC (Oncorhynchus mykiss (rainbow trout)): 1,000 mg/l Exposure time: 28 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 1,000 mg/l Exposure time: 21 d

**2-Methyl-2,4-pentanediol:**

Toxicity to fish	:	LC50 (Gambusia affinis (Mosquito fish)): 8,510 mg/l Exposure time: 96 h
Toxicity to daphnia and other	:	EC50 (Ceriodaphnia dubia (water flea)): 2,800 mg/l



## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

aquatic invertebrates	Exposure time: 48 h
Toxicity to algae/aquatic plants	: ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 429 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	EC10 (Raphidocelis subcapitata (freshwater green alga)): > 429 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 25 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	: NOEC (Bacteria): 200 mg/l Exposure time: 10 d

**Titanium dioxide:**

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l Exposure time: 72 h
Toxicity to microorganisms	: EC50: > 1,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

**Mometasone:**

Toxicity to fish	: LC50 (Menidia beryllina (Silverside)): 0.11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility
	LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
	EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

	Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.34 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility
M-Factor (Chronic aquatic toxicity)	: 100
Toxicity to microorganisms	: EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
	NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility

**Persistence and degradability****Components:****White mineral oil (petroleum):**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 31 % Exposure time: 28 d
------------------	---

**2-Methyl-2,4-pentanediol:**

Biodegradability	: Result: Readily biodegradable. Biodegradation: 81 % Exposure time: 28 d Method: OECD Test Guideline 301F
------------------	---

**Mometasone:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d
------------------	---

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

Stability in water	Method: OECD Test Guideline 314
	: Hydrolysis: 50 %(12 d)
	Method: OECD Test Guideline 111

**Bioaccumulative potential****Components:****2-Methyl-2,4-pentanediol:**

Partition coefficient: n-octanol/water	: log Pow: < 4
	Remarks: Calculation

**Mometasone:**

Bioaccumulation	: Species: Lepomis macrochirus (Bluegill sunfish)
	Bioconcentration factor (BCF): 107.1
	Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water	: log Pow: 4.68
--	-----------------

**Mobility in soil****Components:****Mometasone:**

Distribution among environmental compartments	: log Koc: 4.02
---	-----------------

**Other adverse effects**

No data available

**Section 13: Disposal considerations****Disposal methods**

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**Section 14: Transport information****International Regulations****UNRTDG**

UN number	: UN 3077
UN proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Transport hazard class(es)	: 9

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

Packing group : III  
 Labels : 9  
 Environmental hazards : yes

**IATA-DGR**

UN/ID No. : UN 3077  
 UN proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
 (Mometasone)  
 Transport hazard class(es) : 9  
 Packing group : III  
 Labels : Miscellaneous  
 Packing instruction (cargo aircraft) : 956  
 Packing instruction (passenger aircraft) : 956  
 Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3077  
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,  
 N.O.S.  
 (Mometasone)  
 Transport hazard class(es) : 9  
 Packing group : III  
 Labels : 9  
 EmS Code : F-A, S-F  
 Marine pollutant : yes

**Transport in bulk according to IMO instruments**

Not applicable for product as supplied.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**Section 15: Regulatory information****Safety, health and environmental regulations specific for the product in question**

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable  
 Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable  
 Regulations

**The components of this product are reported in the following inventories:**

AICS : not determined

## Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

DSL : not determined

IECSC : not determined

---

**Section 16: Other information**

Revision Date : 06.04.2024

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
 SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average  
 ACGIH / STEL : Short-term exposure limit  
 SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term  
 SG OEL / PEL (short term) : Permissible Exposure Level (PEL) Short Term

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances

# SAFETY DATA SHEET



## Mometasone Cream Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688405-00018	Date of first issue: 21.05.2017

---

es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN